Lexaria Bioscience (LEXX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lexaria Bioscience has initiated a groundbreaking study to explore the biodistribution of its DehydraTECH-semaglutide formulation using fluorescent imaging in rodents. This research aims to determine whether Lexaria’s technology enhances the effectiveness and safety profile of semaglutide compared to standard oral formulations.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.